Abstract

目的利用人骨髓瘤细胞系ARP1、MM.1S和NCI-H929建立异种移植模型,并对三种细胞移植后生长周期、肿瘤负荷和生物学特点进行比较。方法将ARP1、MM.1S和NCI-H929细胞分别由皮下或尾静脉植入经137Cs照射后的NOD/SCID小鼠,每周观察小鼠的生存情况,监测肿瘤负荷。应用流式细胞术检测小鼠肿瘤组织或骨髓中CD138+细胞的比例。采用免疫荧光检测肿瘤组织细胞的CD138和免疫球蛋白轻链表达。ELISA法检测骨髓和外周血中的免疫球蛋白轻链,micro-CT评价骨病变。结果皮下移植ARP1、MM.1S和NCI-H929细胞的小鼠在两周内均可形成局部肿瘤,免疫荧光检测支持浆细胞肿瘤。尾静脉移植后第20天时可在ARP1组小鼠外周血中检测出κ轻链[(8.2±1.0)ng/ml]。尾静脉移植6周左右,ARP1组小鼠出现体重下降、精神萎靡、下肢逐渐瘫痪等表现,骨髓中能检测到人CD138+CD38+细胞群,予硼替佐米治疗可显著降低肿瘤负荷[(5.7±0.2)%对(21.3±2.1)%,P<0.01]。MM.1S和NCI-H929组小鼠骨髓中未检测到人CD138+CD38+细胞群。结论ARP1、MM.1S和NCI-H929细胞系构建的小鼠模型可作为MM发病机制及临床研究的良好模型。

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.